Aqua Medical's investigational PIMA procedure utilizes the company's proprietary radiofrequency vapor ablation (RFVA) platform delivered through-the-working-channel-of-the-scope catheter to gently ...
Led by Relevance Ventures, the funding will support the completion of Aqua Medical's ongoing U.S. RESTORE-1 pilot study evaluating its investigational PIMA procedure for Type 2 diabetes while funding ...
The PIMA procedure utilizes Aqua Medical's RFVA technology to deliver targeted ablation of up to approximately 60 cm of proximal small intestinal mucosa, aiming to restore metabolic signaling and ...
PLEASANTON, Calif., Sept. 24, 2026 /PRNewswire/ -- Aqua Medical, Inc., a clinical-stage medical technology company advancing Endoscopic Metabolic Restoration for the treatment of Type 2 diabetes, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results